Generic Name and Formulations:
Latanoprostene bunod 0.024%; oph soln; contains benzalkonium chloride.
Bausch Health Companies Inc.
Indications for VYZULTA:
Open-angle glaucoma. Ocular hypertension.
>16yrs: instill 1 drop in the affected eye(s) once daily in the PM.
≤16yrs: not recommended.
Do not exceed recommended dose (may reduce efficacy). History of ocular inflammation: not recommended if active inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Bacterial keratitis may occur (due to multiple-dose containers). Contact lenses (remove; may reinsert lenses 15mins after administration). Pregnancy. Nursing mothers.
Allow at least 5mins between application of other topical oph agents.
Conjunctival hyperemia, eye irritation, eye pain, instillation site pain; increased ocular pigmentation (eg, iris [may be permanent], eyelid, eyelashes), other eyelash/lid changes, macular edema (including cystoid macular edema).
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Congress Passes Bill to Fight Opioid Crisis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure